The TCF7L2 gene is the locus with the strongest association with risk of type 2 diabetes (T2D) in different populations. 1, 2 The rs7903146 single-nucleotide polymorphism (SNP), located in intron 3 and the one with the strongest association to T2D risk, has been the most widely studied TCF7L2 variant. Current evidence suggests that rs7903146 may affect risk of T2D through its effects on enhancer activity 3, 4 resulting in higher TCF7L2 gene expression. [3] [4] [5] The rs7903146 SNP has been found located inside islet-selective open chromatin sites using either formaldehyde-assisted isolation of regulatory elements coupled with high throughput sequencing (FAIRE-seq), 3 or histone H3 lysine methylation modifications as marks of regulatory elements. 4 In addition, the T-allele of rs7903146 (ie, the allele associated with higher risk of T2D) has been found associated with higher TCF7L2 gene expression in human pancreatic islets, 5 and in luciferase reporter assays in the mouse pancreatic MIN6 cell line, 3, 4 and the rat pancreatic 832/13 cell line. 3 More recently Savic et al 6, 7 reported that the TCF7L2 gene harbors several highly conserved cis-regulatory elements that show both in vitro and in vivo enhancer activity. These enhancer elements are located in a 92-kb interval that harbors all the TCF7L2 SNPs, not just rs7903146, associated with T2D risk. The physical overlap between multiple enhancer elements and TCF7L2 variants suggests that this gene may carry more than one causal variant related to the development of T2D. The present letter discusses the implications of these recent findings and presents possible mechanisms in how genetic variants in the TCF7L2 gene may affect the development of T2D.
Causal variants in TCF7L2
Although the 92-kb enhancer-rich region in TCF7L2 harbors several SNPs that have been found associated with risk of T2D, it is commonly assumed the presence of a single causal variant in the region. [8] [9] [10] However, a critical assessment of published results does not rule out the presence of an independent secondary signal. Helgason et al 8 carried out haplotype analysis of SNPs, rs7903146 and rs12255372, and the microsatellite DG10S478 (ie, the three markers that were initially found with the strongest association with T2D 11 ) in Danish and Icelandic populations, and concluded that rs7903146 is the most likely causal variant. However, this same study also did single SNP analysis in West African groups, and although rs7903146 was indeed the marker with the strongest association with T2D (odds ratio (OR) ¼ 1.45, 95% confidence interval (CI) ¼ 1.19-1.77), the rs12255372 showed a weaker but still significant association with T2D (OR ¼ 1.31, 95% CI ¼ 1.01-1.69). Given the nonexistent linkage disequilibrium (LD) between both SNPs in West African populations (YRI r 2 ¼ 0.003), these results are consistent with the presence of at least two different causal variants in the TCF7L2 gene; a stronger signal tagged by rs7903146 and a weaker signal tagged by rs12255372. In contrast, the high LD between these two SNPs in European ancestry populations (CEU r 2 ¼ 0.70) would mask the presence of the secondary signal. Palmer et al 9 in a recent re-sequencing study of a small region of 4.3 kb region in the TCF7L2 gene in African Americans proposed rs7903146 as the causal T2D polymorphism. However, the re-sequenced region did not cover rs12255372 that is 50.5 kb away from rs7903146. It is worth noting that the same research group in an earlier study found both rs7903146 (OR ¼ 1.51, 95% CI ¼ 1.27-1.80) and rs12255372 (OR ¼ 1.20, 95% CI ¼ 1.00-1.43) being associated with risk of T2D in African Americans. 12 Because these two SNPs are not correlated in African Americans (ASW r 2 ¼ 0.01), these results also suggest the presence of at least two causal variants rather than a single causal variant. Maller et al 10 used Bayesian-based fine mapping in the Wellcome Trust Case Control Consortium (WTCCC) GWAS and estimated that 75% of the posterior weight of association in TCF7L2 rests on rs7903146. However, WTCCC data are inadequate to identify a secondary signal even if there is one present, given the high LD in the TCF7L2 gene in European populations. In point of fact, in the only three genes where the WTCCC study found evidence of additional independent signals for T2D, the secondary SNP was in low LD with the index SNP; FTO (index rs17817449 and secondary rs8063946, CEU r 2 ¼ 0.051), CDKN2A (index rs12555274 and secondary rs10965250, CEU r 2 ¼ 0.067), and CDKAL1 (index rs7756992 and secondary rs6456360, CEU r 2 ¼ 0.006). Additional evidence of the relevance of rs12255372 independent from rs7903146 was reported by Parra et al 13 who found that rs12255372 (OR ¼ 1.78, 95% CI ¼ 1.11-2.88) shows a stronger association with T2D in Hispanics relative to rs7903146 (OR ¼ 1.39, 95% CI ¼ 0.89-2.17). Because the minor allele frequency (MAF) of rs12255372 was lower (11.6%) than the MAF of rs7903146 (16.1%) in the studied Hispanic population, the stronger association of rs12255372 cannot be attributed to higher statistical power compared with rs7903146. At last, a recent study found that rs12255372 but not rs7903146 interacts with dietary fat intake in relation to changes in body fat composition. 14 In summary, these results do not rule out the role of rs12255372 as an independent secondary signal in the TCF7L2 gene.
Alternative use of redundant enhancers
In addition to the high LD that may be masking additional signals in TCF7L2 another possibility should be considered, namely that TCF7L2 enhancers may be redundant and they may show personto-person variation on their use. Although the actual number of enhancer elements in the TCF7L2 gene is still unclear, multiple enhancers that show overlapping activity in several cell lines and tissues are present in this region 6, 7 These observations raise the question whether some of those enhancer elements could be showing functional redundancy, as it has been shown for other genes with multiple enhancers. 15, 16 The Encyclopedia of DNA Elements (ENCODE) project has recently depicted a complex picture of chromatin interactions, where on average 3.9 enhancer elements physically interact with 1 transcription start site (TSS) and 2.5 TSSs physically interact with 1 enhancer element. 17 The occurrence of a multitude of enhancer-TSS interactions raises the possibility that some of those interactions are interchangeable (ie, redundant) and that enhancer functional redundancy may be a general feature of gene expression regulation. Whether this is the case or all these enhancer-TSS interactions are strictly necessary for normal gene expression is an open question that requires an answer.
Person-to-person variation in the use of redundant enhancers may add a layer of complexity to gene expression regulation and risk of disease. Recent evidence suggests the presence of interindividual variation in the use of alternative promoters 18, 19 and even usage differences between ethnic groups. 20 The author recently proposed the hypothesis that person-to-person variation in the use of alternative regulatory elements may extend to both gene promoters and enhancers. 21 This hypothesis predicts that, in presence of inter-individual variation in the use of redundant regulatory elements (eg, gene promoters and enhancers) and if functional SNPs are located inside those elements, the observed effects of these functional variants would be attenuated by a factor equal to the proportion of chromosomes in the population using their respective regulatory element. 22 Kasowski et al 23 have recently reported the presence of considerable inter-individual variation in chromatin states as assessed by histone modifications, and binding of cohesin and CTCF. In particular, they found person-to-person variation in enhancer activity without major changes in gene expression, 23 confirming the hypothesis of inter-individual variation in the use of redundant enhancers. It is noteworthy that rare variants (allele frequency o1%) seems to explain in part this variation on enhancer use. 23 Whether TCF7L2 enhancers also show this type of variability is still unknown. Table 1 shows the 28 elements tested for enhancer activity by Savic et al 6, 7 25 had allele-specific luciferase activity in both Huh7 (hepatocarcinoma) and WiDr (colorectal adenocarcinoma) cell lines (rs4132670), or in Huh7 cell line only (rs4506565, and rs12255372), 25 suggesting that these SNPs may have in vivo functional relevance. Although results from these two nonpancreatic tumor-derived cell lines must be interpreted with caution, they stress the need to assess TCF7L2 SNP function in a variety of organs other than pancreas, as it has been shown that TCF7L2 regulates glucose homeostasis through its action in a variety of nonpancreatic tissues such as the liver, 27,28 gut, 29 and brain. 30 Testing the hypothesis of alternative use redundant enhancers in the TCF7L2 gene Testing the hypothesis of person-to-person variation in the use of redundant enhancers in the TCF7L2 gene requires the ability of distinguishing active enhancers from poised/inactive enhancers. Recent work has shown that active enhancers are bi-directionally transcribed resulting in short (o2 kb) noncoding RNAs (enhancer RNAs or eRNAs). 31 Zhu et al 32 reported that expression levels of eRNAs, and therefore enhancer activity, can be reliably predicted by assessing H3K27ac, H3K27me3, H3K79m1, and H3K9ac histone modifications (area under the curve (AUC) ¼ 0.94, and Matthew's correlation coefficient (MCC) ¼ 0.71), and the predictive model seems to be cell-type independent. These observations offer an approach to measure enhancer activity and to test the hypothesis that active enhancers vary from person to person. Preliminary chromatin segmentation analysis of the 92-kb enhancer-rich region of the TCF7L2 gene using available data from different cells/tissues with more than one donor from the NIH Roadmap Epigenomics Mapping Consortium (http://www.roadmapepigenomics.org/) shows variability on chromatin states from tissue-to-tissue and from personto-person for the same tissue (Supplementary Figure 1) . It is noteworthy that the rs12255372 SNP (ie, the one proposed as a secondary signal) is located inside regions with weak enhancer activity in some of the tissues. A crucial next step should be the measurement of enhancer activity by assessing histone modifications in the whole range of tissues where TCF7L2 is expressed. This assessment must move from the traditional 2-dimension approach enhancer x tissue to a more comprehensive 3-dimension scenario subject x enhancer x tissue (ie, to allow for inter-individual variation in the use of redundant enhancers). 
Summary
TCF7L2 is the gene with the strongest association with T2D, and it is generally accepted that the rs7903146 SNP is the single causal variant in this locus. [8] [9] [10] The present letter discussed published data from European and nonEuropean populations and postulated that an independent secondary signal tagged by the rs12255372 SNP is also present in the TCF7L2 gene. The author also discussed recent results that show the presence of multiple enhancers in the TCF7L2 gene, 6, 7 and advanced the hypothesis that these enhancers are redundant and there is person-to-person variability in their use. This hypothesis may explain in part why the rs12255372 shows a weaker association with T2D compared with rs7903146; namely rs12255372 would be located inside elements with weak enhancer activity and with less frequency of use. Preliminary analysis of available data from the NIH Roadmap Epigenomics Mapping Consortium (http://www. roadmapepigenomics.org/) seems to bring support to this hypothesis. A comprehensive assessment of enhancer functional redundancy in all tissues where TCF7L2 is expressed may clarify the interplay between genetic variants and chromatin modifications, and how they jointly affect the development of T2D.
